In all fairness I had two stabs: one quantitative vs one qualitative, and it turns out the qualitative guess was more accurate. I'm surprised by the high mOS for the control group since I thought it would be lower than 11.3 months.
LuPSMA should now definitely be approved by the FDA and it throws into the works many exciting future possibilities, which could also include Veyonda. We still need to see the results for 1200mg NOX66, with the possibility to go up to 2400mg and to be incorporated earlier into the treatment phase along with LuPSMA. This is where the TheraP study results become important since if there is no improved in OS between LuPSMA and Cabazitaxel, then Novartis may look to Veyonda to improve OS for these patients, which would also increase the marketable value for Veyonda. So there's still a lot to look forward to.
A few more slides for those interested, which basically just tells us the same information, just in a more legible way:
In all fairness I had two stabs: one quantitative vs one...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.04M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 67034 | 7.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 21222 | 2 |
View Market Depth
| Last trade - 16.12pm 19/07/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
Day chart unavailable